NATCO Pharma Ltd - Legal Update regarding Risdiplam

NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today updates on the legal proceedings on Risdiplam launch in India.

The Company has received numerous enquiries from investors and patients about the launch, availability and pricing of generic version of Risdiplam in the Indian market. The Company wishes to clarify that the Ld. Single Judge of Delhi High Court had through order dated 24.03.2025 denied Roche's plea for an injunction against the Company for the drug. However, Roche has appealed the decision before the Appellate Bench of the Delhi High Court who has currently directed to maintain the status quo. Due to pendency of the proceedings before the court, the Company does not wish to comment on the status of the proceedings. However, it has been the stand of the Company that it intends to launch the drug only after and subject to successful clarity from the Appellate Bench of the Delhi High Court which is expected shortly.

Subject to the foregoing, the Company has decided to price the product at INR 15,900 MRP consistent with the Company's stand before the court. The Company also intends to offer discount to certain deserving patients through its patient access programme.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 771.25 as compared to the previous close of Rs. 766.40. The total number of shares traded during the day was 74407 in over 4406 trades.

The stock hit an intraday high of Rs. 789.00 and intraday low of 762.55. The net turnover during the day was Rs. 57720041.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 LegalUpdate Risiplam